Issue Date: September 7, 2009
PTC Will Work With Roche And Celgene
PTC Therapeutics has signed a research and licensing agreement with Roche for the development of small molecules with PTC’s Gene Expression Modulation by Small-Molecules, or GEMS, technology. Roche will pay PTC $12 million up front and could pay up to $239 million for each of four central nervous system disease targets if milestones are met. Separately, PTC will apply the GEMS technology to a Celgene oncology drug target. Celgene acquired an option for the research when it invested $20 million in PTC in 2007.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society